QXL138AM, a masked immuno-cytokine (MIC), is emerging as a promising therapy for prostate cancer and other CD138-expressing tumors, including multiple myeloma, pancreatic cancer, and various solid tumors. Currently in Phase 1 clinical trials (NCT06582017) and actively recruiting participants, QXL138AM offers a targeted approach that combines potent anti-tumor activity with reduced systemic toxicity.

QXL138AM integrates interferon alpha 2 (IFNα2) with an antibody targeting CD138, a receptor highly expressed in many cancers. Its unique design includes a masking mechanism that prevents systemic activation of IFNα2, minimizing side effects. The mask is cleaved selectively in the tumor microenvironment by tumor-specific proteases, allowing localized activation of IFNα2. This targeted activation stimulates tumor cell death and enhances the body’s innate and adaptive immune responses, including NK cell activation.

• In Vivo Efficacy: Preclinical studies demonstrated that QXL138AM achieved 69% tumor growth inhibition in prostate cancer models, showcasing its robust anti-tumor potential.
• Preclinical Success: Murine models for multiple myeloma (U266 and H929) also showed significant tumor inhibition, highlighting its versatility across CD138-positive cancers.
• Minimized Toxicity: The masking mechanism ensures minimal systemic side effects by localizing activity to the tumor site.

QXL138AM has been granted FDA Orphan Drug Designation for multiple myeloma and pancreatic cancer, with applications expanding to other solid tumors, including prostate, breast, ovarian, bladder, gastrointestinal, and head and neck carcinomas.

Source.

Trial.